HTGC
Get informed when a big investor buys or sells
+ FollowOvervalued by 187.7% based on the discounted cash flow analysis.
| Market cap | $3.53 Billion |
|---|---|
| Enterprise Value | $3.50 Billion |
| Dividend Yield | $1.88 (12.62%) |
| Earnings per Share | $1.9 |
| Beta | 0.77 |
| Outstanding Shares | 182,760,000 |
| P/E Ratio | 8.51 |
|---|---|
| PEG | - |
| Price to Sales | 7.61 |
| Price to Book Ratio | 1.27 |
| Enterprise Value to Revenue | 8.06 |
| Enterprise Value to EBIT | -61.81 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.9911▲ 235.86% |
|---|---|
| Total Calls | 789,300▼ 42.93% |
| Total Puts | 2,360,900▲ 169.88% |
Holdings and activity of institutional investors.
| Ownership % | 38.88%▲ 11.29% |
|---|---|
| Total Invested | $752.58M▼ 26.99% |
| Investors Holding | 364▼ 5.00% |
No data
This committee provides critical technical analysis and 'scoring' for all tax legislation. Its influence directly shapes the tax policies that profoundly affect the profitability and structure of financial institutions like Hercules Capital.
This committee controls taxation and trade, directly impacting corporate valuations through tax policy. As a financial institution, Hercules Capital's profitability and operational structure are highly sensitive to tax legislation and broad economic policy set by this committee.
This committee regulates the FDA and NIH, which are critical for the drug approval process and R&D in the biotech/life sciences sector, a major investment area for Hercules Capital, directly impacting portfolio company success.
This committee directly regulates the entire financial system, including the SEC, which has oversight over Business Development Companies (BDCs) like Hercules Capital. Decisions on capital requirements, financial regulations, and new securities rules would profoundly impact HTGC.